Overview
- Jang, S.W. et al. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 16329.
- Chan, C.B. et al. (2009) Oncogene 28, 3825.
- Shen, J. and Yu, Q. (2015) Pharmacol. Rep. 67, 217.
Alomone Labs Gambogic amide inhibits the proliferation of K562 human chronic myelogenous leukemia cells.Dose-response curve of Gambogic amide (#G-235) inhibition of K562 cell viability. Cell viability was determined by the XTT method and normalized to control. IC50 was calculated at 204 nM.
- Jang, S.W. et al. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 16329.
- Chan, C.B. et al. (2009) Oncogene 28, 3825.
- Shen, J. and Yu, Q. (2015) Pharmacol. Rep. 67, 217.
Gambogic amide, is a small molecule that mimics nerve growth factor (NGF) and is a selective agonist of TrkA receptor that strongly induces its tyrosine phosphorylation and downstream signaling activation.
Gambogic amide interacts with the cytoplasmic juxtamembrane domain of TrkA receptor and triggers its dimerization. It selectively binds, activates and upregulates the expression of TrkA receptors at nanomolar concentrations but not TrkB or TrkC.
Gambogic acid is a major active ingredient of gamboge, a resin exuded from the Garcinia hanburyi tree in southeast Asia. Gambogic amide also possesses neurotrophic activity in various neural injury animal models and prevents glutamate-induced neuronal cell death1,2.
Gambogic amide shows antiapoptotic activity and demonstrates EC50 value of 5 nM3.
Gambogic amide (#G-235) is a highly pure, synthetic, and biologically active compound.
Powered by Bioz
